• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Alagille Syndrome Companies

    ID: MRFR/Pharma/4863-HCR
    100 Pages
    Rahul Gotadki
    September 2025

    Alagille syndrome is a rare genetic disorder that primarily affects the liver and heart, causing a range of symptoms such as liver damage, bile duct abnormalities, and heart problems.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Top Industry Leaders in the Alagille Syndrome Market

    Alagille Syndrome Market

     


    Latest Alagille Syndrome Companies Updates:


    CANbridge Pharma secures marketing approval for LIVMARLI in Hong Kong: This September 2023 approval marks a significant step towards broader access to the medication for patients with Alagille Syndrome in the region.


    Patient advocacy groups like the Alagille Syndrome Alliance and Chiari & Associates for Alagille Syndrome (CAFAS) play a vital role in raising awareness, providing support and resources, and funding research for improved diagnosis, treatment, and cure for Alagille Syndrome.


    Online communities and forums offer valuable information and connection for individuals living with Alagille Syndrome and their families.


    List of Alagille Syndrome Key companies in the market:



    • Sanofi AG

    • Teva Pharmaceutical Industries Ltd.

    • Allergen Plc

    • Lannett

    • Albireo Pharma, Inc.

    • AstraZeneca Plc

    • Novartis AG

    • Pfizer, Inc.

    • Shire

    • Bristol-Myers Squibb Company

    • GlaxoSmithKline Plc